XTalks

JANUARY 22, 2025

Since its introduction, it has become a cornerstone therapy for heart failure patients, particularly after receiving a Class 1 recommendation from the American College of Cardiology (ACC) and the American Heart Association (AHA) in 2016.

Sales 104

Sales FDA Approval Drugs Marketing 104

Scienmag

APRIL 20, 2021

EB 2021 will feature the latest insights into COVID-19, cancer, heart disease and more Embargoed press materials are now available for the virtual Experimental Biology (EB) 2021 meeting, featuring cutting-edge multidisciplinary research from across the life sciences.

Life Science 75

Life Science Research Cardiology Medicine 75

XTalks

DECEMBER 2, 2024

The US Food and Drug Administration (FDA) has approved AOP Health’s landiolol injection, marketed as Rapiblyk, for the treatment of atrial fibrillation (Afib) and atrial flutter in critical care settings.

Trials 104

Trials Marketing FDA Approval Life Science 104

XTalks

NOVEMBER 26, 2024

The US Food and Drug Administration (FDA) has approved Attruby (acoramidis) , marking a significant advancement for patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). This progressive disease occurs when misfolded transthyretin (TTR) proteins form amyloid deposits in the heart, leading to cardiac dysfunction.

Genetic Disease 105

Genetic Disease Genetics Protein Clinical Development 105

pharmaphorum

OCTOBER 2, 2020

One of the Sector Deal 2 commitments within the Government’s Life Sciences Industrial Strategy, the NPRCs are the first NIHR-funded research infrastructure that is 100% dedicated to delivering commercial research.

Clinical Trials 92

Clinical Trials Clinical Trials Clinical Research Life Science 92

XTalks

NOVEMBER 21, 2024

The US Food and Drug Administration (FDA) has granted Breakthrough Device clearance to Ultromics’ EchoGo Amyloidosis device through its Total Product Lifecycle Advisory Program (TAP). Cardiac amyloidosis, a serious and often underdiagnosed heart condition, poses significant diagnostic challenges even for experienced clinicians.

Production 105

Production Protein Life Science Trials 105

FDA Law Blog

JUNE 2, 2022

This meeting brings together industry, regulators, academics, and patients to discuss global and local challenges in the life sciences industry. Hyman, Phelps & McNamara, P.C.’s s James Valentine and Ellis Unger will be presenting at the DIA 2022 Global Annual Meeting held this June 19-23 in Chicago, IL.

Cardiology 52

Cardiology Life Science Development Drugs 52

pharmaphorum

OCTOBER 2, 2020

One of the Sector Deal 2 commitments within the Government’s Life Sciences Industrial Strategy, the NPRCs are the first NIHR-funded research infrastructure that is 100% dedicated to delivering commercial research.

Clinical Trials 52

Clinical Trials Clinical Trials Clinical Research Life Science 52

pharmaphorum

DECEMBER 16, 2021

According to Abhishek, COVID allowed Wellthy to focus on areas in which it could genuinely have an impact, and the company evolved to become a platform that enables life science, & MedTech companies to build and deploy regulatory compliant digital health solutions. About the author.

Pharma Companies 40

Pharma Companies Cardiology Life Science Marketing 40

The Pharma Data

FEBRUARY 21, 2022

Our leadership in cardiology, radiology and women’s health is recognized worldwide, and we are expanding our presence in oncology, working tirelessly to bring forward new approaches that can change the treatment paradigm for patients,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division.

Radiology 52

Radiology Cardiology Development Production 52

XTalks

SEPTEMBER 4, 2024

The data, presented at the European Society of Cardiology Congress 2024, suggest that vutrisiran could significantly reduce the risk of death and heart-related issues, marking a potential treatment breakthrough.

Trials 52

Trials RNA Protein Gene Editing 52

XTalks

AUGUST 2, 2023

With Blackstone Life Sciences, up to €300 million (around $315 million USD) will be invested to accelerate pivotal studies and clinical development programs for formulating the subcutaneous delivery of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma. 21) Merck KGaA By: Ayesha Rashid, Ph.D.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

NOVEMBER 19, 2021

This is a part of the precision cardiology approach and could lead to their use as prognostic indicators. The Double-Edged Sword of Cardiac Biomarkers.

Clinical Trials 98

Clinical Trials Clinical Trials Trials In-Vitro 98

The Pharma Data

MAY 31, 2022

The Company’s cell+gene platform harnesses the power of cells to create new medicines for neurology, cardiology, immunology, and ophthalmology indications. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. For more information, visit www.bluerocktx.com.

Trials 52

Trials Engineer Clinical Trials Clinical Trials 52

XTalks

JUNE 11, 2024

Treatment options like it not only have the potential to improve patient care but also to influence future research directions and treatment strategies in interventional cardiology.

Drugs 52

Drugs Drug Delivery Cardiology Marketing 52

Pharma Marketing Network

JANUARY 12, 2023

Liz Paulson, Associate Vice President, Life Sciences for the Healthcare Business of LexisNexis® Risk Solutions, is recognized with HBA’s Strategic Transformation Achievement Recognition (STAR) volunteer honor. Christi Shaw, Chief Executive Officer, Kite, a Gilead Company, was selected as the 2023 Woman of the Year.

Life Science 52

Life Science Manufacturing Cardiology Development 52

XTalks

JULY 10, 2023

We did not get a Class II certification for diabetes only, or orthopedics or cardiology; we got a disease-agnostic certification. Now, as we develop new predictive algorithms, whether that is in diabetes, cardiology, respiratory or oncology, we can bring those algorithms to our platform because it is disease-agnostic.

Life Science 52

Life Science Cardiology Regulation Pharma Companies 52

XTalks

FEBRUARY 16, 2024

This approval provides patients with the first-ever treatment option for severe frostbite,” said Norman Stockbridge, MD, PhD, director of the Division of Cardiology and Nephrology in the FDA’s Center for Drug Evaluation and Research (CDER).

Cardiology 59

Cardiology Gene Therapy Drugs Branding 59

The Pharma Data

FEBRUARY 24, 2022

The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.

Clinical Development 52

Clinical Development Development Cardiology Life Science 52

XTalks

SEPTEMBER 26, 2024

September 29 is World Heart Day 2024, an initiative by the World Heart Federation to raise awareness about cardiovascular diseases (CVDs) and the importance of heart health. As one of the leading causes of death globally, CVDs claim over 20 million lives each year.

Protein 98

Protein Life Science Cardiology Development 98

The Pharma Data

SEPTEMBER 29, 2021

The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.

Clinical Development 52

Clinical Development Development Clinical Trials Clinical Trials 52

XTalks

AUGUST 4, 2022

During the webinar, Dr. Shreenivas gave examples from cardiology and oncology which show that race and ethnicity do matter for medical problems. This gives hope that the diversity of the US population can be mirrored in clinical trials if the life sciences industry focuses more on diversity and inclusion.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52

XTalks

FEBRUARY 6, 2024

Vice President of the Medical Department and Cardiology therapeutic lead, and Heather Lohr, Sr. Srivastava recently spoke on a webinar where he shared insights on the imperative need to bridge this research gap and include more CKD patients in cardiovascular clinical trials. Director of Clinical Trial Management.

Clinical Trials 96

Clinical Trials Clinical Trials Trials Clinical Research 96

XTalks

JULY 7, 2023

Milestone Pharmaceuticals Inc., a Canadian biopharmaceutical firm specializing in cardiovascular therapies, recently reported positive results from a Phase III clinical trial of its leading candidate, etripamil nasal spray, for the treatment of paroxysmal supraventricular tachycardia (PSVT).

Clinical Trials 98

Clinical Trials Clinical Trials Trials Drugs 98

XTalks

APRIL 15, 2021

Dr. Benoit Tyl, MD, FESC, medical and scientific director, cardiology at Servier, says that the disconnect between correlation and causality in cardiovascular disease trials is partially responsible for the lack of approved HFpEF therapies. However, these drugs have shown limited effectiveness in treating HFpEF.

Development 98

Development Drugs Genome Genomics 98

XTalks

FEBRUARY 9, 2024

For healthcare professionals and stakeholders in the life sciences sector, understanding the top-performing cardiovascular drugs is not just about recognizing their financial success.

Sales 59

Sales FDA Approval Drugs Marketing 59

The Pharma Data

OCTOBER 28, 2021

The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Branding 52

XTalks

FEBRUARY 8, 2024

Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, life sciences and pharmaceutical sectors. Understanding the market dynamics of diabetes treatments becomes crucial for professionals across these industries.

Sales 52

Sales Insulin FDA Approval Drugs 52

XTalks

JANUARY 3, 2025

For the first time in the US, adults living with familial chylomicronemia syndrome (FCS) have an FDA-approved treatment option.

FDA Approval 59

FDA Approval Drugs Clinical Trials Clinical Trials 59

XTalks

JANUARY 19, 2024

References The Green Journal. Radiotherapy and Oncology. Relative Biological Effectiveness (RBE), RBE~3-7 but depends on AD, biological endpoint, tissue type as discussed by Donika Plyku, PhD (FDA) Dawson, Laura A.,

DNA 66

DNA Radiology FDA Approval Development 66

Scienmag

DECEMBER 8, 2020

Odds of exceeding maximum contaminant levels were significantly greater for water systems in the Southwest and serving Hispanic communities A new national study of public water systems found that arsenic levels were not uniform across the U.S., even after implementation of the latest national regulatory standard.

Contamination 41

Contamination Life Science Cardiology Medicine 41

pharmaphorum

FEBRUARY 8, 2022

A notable example is the relative lack of Black participants in cardiology trials. Natalie Yeadon is the CEO and co-founder of Impetus Digital, where she helps life science clients virtualise their meetings and events and create authentic relationships with their customers. About the author.

Clinical Trials 116

Clinical Trials Clinical Trials Trials Cardiology 116

XTalks

SEPTEMBER 11, 2024

It wasn’t until 1999, when the American Heart Association released its Guide to Preventive Cardiology for Women , that the medical field acknowledged that women show different symptoms of the disease than men. Another example is heart disease, the leading cause of death for both men and women in the US.

Clinical Trials 103

Clinical Trials Clinical Trials Trials Hormones 103

XTalks

DECEMBER 19, 2024

percent, including impacts from its 2023 acquisition of cardiology medtech company Laminar. The company is reporting an operational sales growth of five to six percent in 2024 and anticipates an adjusted earnings per share (EPS) growth of 7.3 If you want your company to be featured on Xtalks.com, please email ayeshar@xtalks.com.

Sales 97

Sales FDA Approval Licensing Licensing 97

XTalks

NOVEMBER 22, 2024

NewAmsterdam Pharma announced promising results from its Phase III TANDEM clinical trial, evaluating a fixed-dose combination of obicetrapib and ezetimibe. This therapy targets patients with high cardiovascular risk due to atherosclerotic cardiovascular disease (ASCVD), ASCVD risk factors or heterozygous familial hypercholesterolemia (HeFH).

Trials 105

Trials Clinical Research Clinical Trials Clinical Trials 105

XTalks

MARCH 14, 2025

Kestra Medical Technologies, Ltd. announced the closing of its upsized initial public offering (IPO) on March 7, 2025, raising approximately $202 million. The company offered 11,882,352 common shares at $17 per share, with trading beginning on Nasdaq on March 6 under the ticker KMTS.

Marketing 59

Marketing Life Science Cardiology 59